{
  "docId": "019dd923-622c-750b-8b9a-2a2468219173",
  "docSlug": "ce565b841c40",
  "documentTitle": "Nevro Corp. (NVRO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Kir Kahlon",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-01-07 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 97,
  "pageCount": 239,
  "prevPage": 96,
  "nextPage": 98,
  "slideType": "testimonial",
  "function": "illustrate_case",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "Case study #3 of 5.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/97",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-97",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "He stated that patients started off well, only to experience a quick collapse in efficacy.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b33e-6e647c0820ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.06,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "Case study #3: One of the most prominent KOL’s in the field – a former Nevro consultant and speaker – described his initial enthusiasm for Nevro’s device, implanting 80 within the first 18 months. He stated that patients started off well, only to experience a quick collapse in efficacy. As a well-known figure, he regularly conducts group sessions with other “busy implanters,” whose experience with high frequency failure was similar to the point that they also became “hesitant to use the product.”",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ed30ba00-05d4-4e0a-a8c1-dfdd1a489255",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.06,
        "y": 0.48
      },
      "kind": "quote",
      "text": "“When Nevro first came out I was using primarily Boston Scientific. At the time I thought it was the best product on the market but I was convinced to try Nevro. I had a couple of patients that weren’t getting relief with Boston, so we hooked them up to a Nevro device and it did very well. So that precipitated my journey from Boston Scientific to Nevro several years ago. And probably the first 18 months I put in close to 80 Nevro implants and did 100 trial implants which is a fair amount.”",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "29679fb2-e4db-4bfc-a432-997040bd0db8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.06,
        "y": 0.32
      },
      "kind": "quote",
      "text": "“I’ve consulted at length for Boston Scientific, Abbott, Nuvectra, and of course Nevro over the course of my career. I have been doing implants for 20 years. I’ve put in probably several thousand over the years and probably do about 5 or more per month. I actually am [role redacted] at [medical journal name redacted] which is kind of the bible for neuromodulation. I would review papers on stimulation every month as a peer-reviewer so I’m quite versed with the field.”",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "789b20bb-4a28-4e1d-a0b5-5025321bcaea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.06,
        "y": 0.65
      },
      "kind": "quote",
      "text": "“What I noticed is that initially almost everybody did really well and subsequently there was a big fall off. We would hold round tables where we would have 15 implanter leaders and I and two other moderators would talk about the space in general and I found that I was not alone and that other busy implanters also had the same experience, where initially things looked good and then there was a significant drop off to where many doctors were hesitant to use the product.” -Ex-Nevro consultant/speaker and one of the most prominent KOL’s in the space",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fcd7eed0-34b2-411f-b039-455a054ccde4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“I’ve consulted at length for Boston Scientific, Abbott, Nuvectra, and of course Nevro over the course of my career. I have been doing implants for 20 years. I’ve put in probably several thousand over the years and probably do about 5 or more per month. I actually am [role redacted] at [medical journal name redacted] which is kind of the bible for neuromodulation. I would review papers on stimulation every month as a peer-reviewer so I’m quite versed with the field.” — Ex-Nevro consultant/speaker and one of the most prominent KOL’s in the space",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b33e-716cf301a541",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.06,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "Source: Consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f68dd460-3847-4234-90ef-e2640c8ae3b8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.8,
        "x": 0.06,
        "y": 0.09
      },
      "kind": "title",
      "text": "7. Nevro’s explants crisis is pervasive yet unknown to most investors: case studies of 5 KOL’s",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "71b81bfd-2ef0-44a0-be13-c3c1fa5b3bb4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "Scorpion Capital | Nevro (NYSE: NVRO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f14a7b4-79c3-45e6-841e-4a8dda7389bb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 150,
      "from": 51,
      "beatId": "903c076a-f368-4ca1-844c-277874c1afb2",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Victory",
      "beatSlug": "overcoming-monster-the-victory",
      "evidence": "The deck presents a conclusion that Nevro's problems are insurmountable",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}